🔍

Sudeep Pharma Limited (SUDEEPPHRM)

₹1,000.70 -0.73% last close, 16 Oct

📊 NSE: SUDEEPPHRM 🏢 Pharmaceuticals 📢 Latest filing: 05 Oct 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Sudeep Pharma's revenue was ₹158 Cr (+26.6% year on year, -13.0% on the previous quarter), and net profit ₹40.6 Cr (+30.9% year on year); the operating margin was 34.7%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹158	+26.6%	-13.0%
Operating profit	₹54.9	+24.8%	-12.8%
Net profit	₹40.6	+30.9%	-17.2%
EPS (₹)	3.59	+13.2%	-17.1%
Operating margin	34.7%	—	—

Full quarterly financials → Results calendar →

SUDEEPPHRM delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 54.08% of the SUDEEPPHRM shares traded on NSE were taken to delivery, against the stock's own 20-session average of 53.43%. That is close to its usual level. Volume was 0.5 times its average, well below normal. It closed at a price band (circuit) on 3 sessions in about the last 20.

54.08%Delivery, 16 Oct

53.43%Own 20-session average

0.5×Volume vs its average

₹1,000.70NSE close · -0.73%

Delivery in the last 5 sessions: 51.5% · 62.7% · 41.1% · 48.5% · 54.1%

Delivery across the market →Circuit stocks →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Sudeep Pharma: Sendhil Pani Steps Down as MD of US Subsidiary and SMP Effective Oct 2, 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 05 Oct 2026, 05:02 PM

Sudeep Pharma Limited announced a change in its Senior Management Personnel (SMP) following the completion of contractual arrangements with Mr. Sendhil Pani. Mr. Pani served as the Managing Director of the wholly owned subsidiary, Sudeep Pharma USA Inc. His cessation as SMP became effective on October 2, 2026, as per Regulation 16(1)(d) of the SEBI Listing Regulations. The intimation was formally submitted to the stock exchanges on October 5, 2026.

Cessation of Mr. Sendhil Pani as Senior Management Personnel effective October 2, 2026
Change arises due to the completion of contractual arrangements with the company
Mr. Pani served as Managing Director of wholly owned subsidiary Sudeep Pharma USA Inc.
Filing made under Regulation 30 of SEBI Listing Regulations on October 5, 2026

💡 Track announcements regarding the appointment of a successor for the US subsidiary leadership, particularly as the company transitions to a direct-to-customer model in overseas markets.

Sudeep Pharma to Attend Nuvama Emerging India CEO Forum on September 28, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 23 Sep 2026, 03:12 PM

Sudeep Pharma Limited has scheduled participation in the Nuvama Emerging India CEO Forum 2026 in Mumbai on September 28, 2026, from 10:00 am onwards. Company officials will participate in 1x1 and group meetings with institutional investors and analysts. The company explicitly stated that discussions will be based strictly on publicly available information without any unpublished price sensitive information (UPSI).

Investor meeting scheduled for September 28, 2026, starting at 10:00 am onwards
Format comprises 1x1 and group meetings organized by Nuvama Emerging India CEO Forum 2026 in Mumbai
Company confirmed that no unpublished price sensitive information (UPSI) will be discussed

💡 Track subsequent post-meet presentation uploads or transcripts on exchange filings for any qualitative management commentary regarding battery materials or infant nutrition segments.

Sudeep Pharma Schedules Analyst and Institutional Investor Plant Visit on Sep 23-24, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 16 Sep 2026, 11:22 AM

Sudeep Pharma Limited has scheduled an analyst and institutional investor meeting in Gujarat on September 23rd and 24th, 2026, starting at 11:00 am. The interaction will take the form of a physical plant visit. The company affirmed that discussions will rely solely on publicly available information without any unpublished price sensitive information (UPSI).

Meeting dates scheduled for 23rd & 24th September 2026
Session starts from 11:00 am onwards
Nature of interaction is an on-site Plant Visit in Gujarat
Company confirmed no Unpublished Price Sensitive Information (UPSI) will be shared

💡 Watch for any post-visit presentations or disclosures filed with the exchanges following the September 23-24 plant visits.

27% Revenue Growth in Q1 FY27; Specialty Ingredient Sales Surpass Full Year FY26 Levels

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 11 Aug 2026, 04:12 PM

Sudeep Pharma reported a strong 27% YoY consolidated revenue growth for Q1 FY27, driven by a 31% surge in the Pharma, Food, and Nutrition segment. A standout performance was seen in the Absorbis Bisglycinates portfolio, where Q1 sales alone exceeded the total sales achieved in the entire previous financial year. Despite a 50% spike in phosphoric acid costs, management is maintaining an EBITDA margin target of 37-38% through price pass-throughs. The company is also progressing on its battery materials facility (25,000 MT) with a strict non-China supply chain strategy to ensure US market compliance.

Consolidated revenue grew 27% YoY, led by 31% growth in the Pharma and Nutrition segment.
Absorbis Bisglycinates Q1 sales surpassed the total sales achieved during the entire previous financial year.
Phosphoric acid prices increased by approximately 50% during the quarter, with price pass-throughs expected to offset impact in Q2.
Maintained EBITDA margin guidance of 37-38% despite raw material and logistics headwinds.
Greenfield expansion in Dahej to add 51,200 MT, bringing total capacity to 123,446 MT.

💡 Watch for the margin trajectory in Q2 FY27 to confirm the successful pass-through of raw material costs and monitor the execution timeline of the Dahej facility which nearly doubles existing capacity.

Sudeep Pharma corrects AGM attendance count to 44 members

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 06 Aug 2026, 04:47 PM

Sudeep Pharma Limited has issued a clarification regarding its Annual General Meeting (AGM) held on August 4, 2026. The company corrected a clerical error in its previous filing where the number of attendees was incorrectly stated as 45. The revised and correct number of attendees is 44, comprising 5 from the promoter group and 39 from the public. This update is purely administrative and does not affect the company's financial performance or strategic outlook.

Total AGM attendees corrected from 45 to 44
Public attendee count revised from 40 to 39
Promoter group attendance confirmed at 5 members
Correction pertains to the AGM held on 4th August 2026

💡 No action is required as this is a routine administrative correction. Investors should continue to monitor the progress of the Greenfield expansion in Dahej, which aims to add 51,200 MT of capacity.

Sudeep Pharma releases Q1 FY27 earnings call audio recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Aug 2026, 05:05 PM

Sudeep Pharma has made the audio recording of its Q1 FY27 earnings call, held on August 5, 2026, available to the public. The call likely addresses the company's progress on its 51,200 MT Greenfield expansion in Dahej and the integration of the 85% stake in NSS (Ireland) acquired in May 2025. Investors should look for updates on the 25,000 MT battery material facility, which is expected to start contributing to revenue by FY27, supporting the company's 26% expected growth rate.

Earnings call for Q1 FY27 conducted on August 5, 2026
Management discussion covers the 51,200 MT Greenfield expansion in Dahej
Updates provided on the 25,000 MT battery material facility targeted for FY27
Recording follows the 85% stake acquisition of NSS in Ireland to enter the infant nutrition market

💡 Investors should review the recording or upcoming transcript for management's commentary on the 63-64% gross margin target and the execution timeline for the Dahej facility.

Sudeep Pharma Shareholders Approve ESOP Scheme 2025 and Dividend at 37th AGM

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 05 Aug 2026, 12:40 PM

Sudeep Pharma Limited successfully passed all 11 resolutions at its 37th Annual General Meeting held on August 4, 2026. Key approvals include the adoption of FY26 financial statements, declaration of a dividend, and the implementation of the Sudeep Pharma Employee Stock Option Scheme 2025. While most resolutions passed with near-unanimous support, the ESOP-related resolutions (Items 7, 8, and 9) saw a minor dissent of approximately 3.99% from voting shareholders. The company also confirmed the re-appointment and remuneration adjustment for Whole Time Director Ajay Shrirang Kandelkar.

11 resolutions passed with requisite majority during the AGM held via video conferencing
35,491 total shareholders were on record as of the July 28, 2026, record date
ESOP Scheme 2025 resolutions received 4,107,854 votes against, representing 3.99% of total valid votes
Total valid votes cast for the adoption of financial statements reached 103,015,735
Remuneration change for Whole Time Director Ajay Shrirang Kandelkar approved effective April 1, 2026

💡 Investors should monitor the specific dividend payout timeline and the potential equity dilution impact once the 2025 ESOP Scheme is implemented. The adoption of new Articles of Association (AOA) should also be reviewed for any shifts in corporate governance norms.

27% Revenue Growth in Q1FY27; Rs 300 Cr Battery Material Project on Track for March 2027

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 04 Aug 2026, 09:36 PM

Sudeep Pharma reported a strong Q1FY27 with revenue growing 27% YoY to Rs 158.3 cr and PAT increasing 30% to Rs 40.6 cr. The company is aggressively diversifying into the EV battery materials segment (SAM project) with a Rs 300 cr investment, targeting 25,000 MT capacity by March 2027. Despite headwinds in the European market (NSS subsidiary) and elevated logistics costs, EBITDA margins remained resilient at 34.7%. The company also signed two additional MoUs with South Korean manufacturers for battery-grade iron phosphate.

Revenue from operations grew 27% YoY to Rs 158.3 cr in Q1FY27.
Profit After Tax (PAT) increased 30% YoY to Rs 40.6 cr with a 25.6% margin.
Battery Materials project (SAM) Phase 1 on track for March 2027 commissioning with a Rs 300 cr investment.
Signed 2 additional MoUs with leading South Korean CAM manufacturers for battery materials.
Greenfield expansion in Dahej to add 51,200 MT, targeting a total core capacity of 123,446 MT.

💡 Monitor the execution timeline of the SAM battery materials project scheduled for March 2027 and the conversion of MoUs into firm off-take contracts. Watch for demand recovery in the European market which currently remains subdued due to high energy costs.

27% Revenue Growth in Q1 FY27; ₹300 Cr Battery Material Project on Track for March 2027

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 04 Aug 2026, 07:04 PM

Sudeep Pharma reported a strong Q1 FY27 with revenue growing 27% YoY to ₹158.3 Cr and PAT increasing 30% to ₹40.6 Cr. The company is aggressively diversifying into the EV supply chain via its Sudeep Advanced Materials (SAM) project, a ₹300 Cr investment in Dahej targeting 25,000 MT of battery-grade iron phosphate. While EBITDA margins saw a slight compression of 40 bps to 34.7%, the company maintained a healthy PAT margin of 25.6%. A massive greenfield expansion is also underway to increase core pharma/nutrition capacity by 51,200 MT, representing a ~70% increase over current levels.

Revenue from operations grew 27% YoY to ₹158.3 Cr in Q1 FY27
PAT increased 30% YoY to ₹40.6 Cr with a margin of 25.6%
₹300 Cr investment in Battery Materials (SAM) project on track for March 2027 commissioning
Total manufacturing capacity to expand from 72,246 MT to 123,446 MT via Greenfield project
Signed 2 additional MoUs with South Korean manufacturers, totaling 8 MoUs for the battery segment

💡 Monitor the execution timeline of the Dahej Greenfield facility and the SAM project commissioning by March 2027. Investors should also track the conversion of the 8 MoUs into firm off-take agreements and the recovery of demand in the European market (NSS subsidiary).

29.8% YoY PAT Growth in Q1 FY27; Revenue Reaches ₹158.27 Cr

🟢 POSITIVE ⭐ 6/10

EARNINGS 📅 04 Aug 2026, 05:58 PM

Sudeep Pharma reported a consolidated revenue of ₹158.27 cr for Q1 FY27, marking a 26.7% increase over Q1 FY26. Net profit grew 29.8% YoY to ₹40.59 cr, although it declined 16.4% sequentially from Q4 FY26. The company maintains a significant cash buffer with ₹75.46 cr of unutilized IPO proceeds currently held in bank deposits, intended for machinery procurement. Operational performance remains steady with an EPS of ₹3.59, up from ₹2.84 in the year-ago period.

Consolidated Revenue from operations increased 26.7% YoY to ₹158.27 cr from ₹124.92 cr.
Net Profit for the quarter rose to ₹40.59 cr, a 29.8% increase compared to ₹31.27 cr in Q1 FY26.
Unutilized IPO proceeds stand at ₹75.46 cr as of June 30, 2026, primarily earmarked for Nandesari facility machinery.
Employee benefit expenses increased to ₹14.34 cr from ₹12.24 cr in the corresponding quarter last year.
Total comprehensive income for the period stood at ₹40.53 cr after accounting for foreign operation translation losses.

💡 Investors should monitor the deployment timeline of the ₹75.46 cr unutilized IPO proceeds into machinery, which is critical for capacity ramp-up. Additionally, track the progress of the Dahej greenfield expansion and battery materials facility, which are expected to drive long-term growth by FY27.

₹642.3 Cr Revenue in FY26; 25,000 MT Battery Material Plant on Track for 2027

🟢 POSITIVE ⭐ 6/10

ROUTINE 📅 04 Aug 2026, 05:14 PM

Sudeep Pharma reported a strong FY 2025-26 with revenue of ₹642.3 crore and a PAT margin of 27.1%. The core Pharma and Nutrition segment grew 10% to ₹362 crore, though growth was limited by near-optimal capacity utilization. A major strategic shift is underway with a 25,000 MT battery material facility in Dahej targeted for April 2027, which has already secured 700 MT in initial orders. Shareholders ratified the 2025 ESOP scheme and approved the dividend for the fiscal year.

Reported FY 2025-26 revenue of ₹642.3 crore with a robust EBITDA margin of 34.6%.
Advanced battery material facility at Dahej (25,000 MT capacity) is on track for April 2027 commissioning.
Secured initial commercial orders of approximately 700 metric tonnes for battery-grade materials ahead of plant completion.
Pharma, Food, and Nutrition segment revenue grew 10% to ₹362 crore, contributing 56% of total revenue.
Exports remained a core strength, accounting for approximately 60% of the total revenue mix.

💡 Investors should monitor the execution timeline of the Dahej battery material facility (April 2027) and the customer qualification progress at the new Nandesari facility to address current capacity constraints.

August 5, 2026: Sudeep Pharma to Host Q1FY27 Earnings Conference Call

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Jul 2026, 12:06 PM

Sudeep Pharma Limited has scheduled its earnings conference call for August 5, 2026, at 11:00 AM IST to discuss financial results for the quarter ended June 30, 2026. The call will be hosted by Nuvama Wealth Management and will feature the Managing Director, Director, and CFO. This interaction follows a period of significant strategic shifts, including the 85% stake acquisition of NSS (Ireland) and ongoing greenfield expansions. Investors will be looking for updates on the integration of recent acquisitions and the progress of the Dahej manufacturing facility.

Earnings call scheduled for Wednesday, August 5, 2026, at 11:00 AM IST
Management representation includes MD Sujit Bhayani, Director Shanil Bhayani, and CFO Ketan Vyas
Discussion to cover operational and financial performance for the quarter ended June 30, 2026
Company previously reported a revenue of ₹162.67 cr and PAT of ₹46.78 cr in the Sep 2025 quarter
Ongoing expansion plans include adding 51,200 MT capacity at Dahej to reach a total of 123,446 MT

💡 Investors should listen for management commentary regarding the execution timeline of the 25,000 MT battery material facility and the margin impact of the NSS acquisition integration.

₹1.50 Final Dividend: Sudeep Pharma Sets July 23, 2026, as Record Date

🟡 NEUTRAL ⭐ 5/10

DIVIDEND 📅 10 Jul 2026, 03:23 PM

Sudeep Pharma Limited has fixed July 23, 2026, as the record date for its final dividend of ₹1.50 per equity share for the financial year 2025-26. This dividend is based on a face value of ₹1 per share, representing a 150% payout. The distribution is subject to shareholder approval at the 37th Annual General Meeting (AGM) scheduled for August 4, 2026. At the current market price of ₹828.9, the dividend yield stands at approximately 0.18%.

Final dividend of ₹1.50 per equity share recommended for FY 2025-26
Record date for determining shareholder entitlement is July 23, 2026
37th Annual General Meeting (AGM) to be held on August 4, 2026
Dividend payout is based on a face value of ₹1 per share
Payment will be processed within the stipulated time period post-AGM approval

💡 Investors interested in the dividend must hold the shares in their demat account by the record date of July 23, 2026. Monitor the AGM outcome on August 4, 2026, for formal approval of the payout.

July 23 Record Date for Final Dividend; 37th AGM Scheduled for August 4

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Jul 2026, 02:13 PM

Sudeep Pharma Limited has announced its 37th Annual General Meeting (AGM) for August 4, 2026. The company has established July 23, 2026, as the record date for the final dividend, with the payment date set for August 7, 2026. Shareholders can now access the Integrated Annual Report for FY 2025-26 via the company's website. This filing is administrative, focusing on shareholder communication and statutory timelines for the upcoming meeting.

37th Annual General Meeting scheduled for August 4, 2026, at 11:00 AM via video conferencing
Record date for the final dividend is fixed as July 23, 2026
Dividend payment date is scheduled for August 7, 2026
Remote e-voting period runs from August 1, 2026, to August 3, 2026
Integrated Annual Report for FY 2025-26 made available via digital links for all shareholders

💡 Investors should review the Integrated Annual Report for updates on the Dahej greenfield expansion (51,200 MT) and the 25,000 MT battery material facility progress.

₹1.50 Dividend and FY26 Revenue of ₹338.5 Cr Announced in 37th AGM Notice

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 10 Jul 2026, 01:35 PM

Sudeep Pharma has issued its 37th AGM notice for August 4, 2026, proposing a dividend of ₹1.50 per share (150% payout). The company reported FY 2025-26 revenue of ₹338.51 cr, a 5.1% decline from the previous year, though Profit After Tax (PAT) grew 12.3% to ₹107.58 cr. Key agenda items include the re-appointment of Whole Time Director Mr. Ajay Kandelkar with a revised remuneration of ₹114.97 lakhs. Investors should note the high PAT margin of 31.8% despite the slight revenue contraction.

Proposed dividend of ₹1.50 per equity share of face value ₹1 (150% payout ratio).
FY 2025-26 Revenue stood at ₹338.51 cr compared to ₹356.73 cr in FY 2024-25.
Profit After Tax (PAT) increased to ₹107.58 cr from ₹95.75 cr in the previous year.
Proposed remuneration for Whole Time Director Mr. Ajay Kandelkar is ₹114.97 lakhs p.a.
Company maintains a strong PAT margin of 31.8% for the financial year ended March 31, 2026.

💡 Monitor the approval of the dividend and the progress of the Greenfield expansion in Dahej, which is expected to add 51,200 MT of capacity and drive future revenue growth.

View All SUDEEPPHRM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In H1 FY26, the Specialty business contributed 60% of revenue (growing significantly with the NSS acquisition), while the Pharma, Food, and Nutrition segment contributed 40%. In Q2 FY26, the Pharma, Food, and Nutrition business saw a 7% YoY decline, while Specialty ingredients grew 2% when excluding the INR 20 Cr contribution from NSS.

Geographic Revenue Split

International business (including exports) contributed 61% of total revenue in H1 FY26, while domestic sales accounted for 39%. The U.S. remains the company's largest regulated market.

Profitability Margins

Gross margins have returned to a historical average of 63%-64% in FY26 after an exceptional FY25 where raw material price drops were not immediately passed to customers. PAT margin stood at 27.1% in Q2 FY26 compared to 32.4% in Q2 FY25.

EBITDA Margin

EBITDA margin for Q2 FY26 was 38.0%, a decrease from 43.4% in Q2 FY25. H1 FY26 EBITDA margin was 37.9% compared to 40.9% in H1 FY25, reflecting upfront investments in global sales teams and warehousing.

Capital Expenditure

The company has a Greenfield project outlay of INR 150 Cr for a 51,200 MT facility. As of September 2025, INR 120 Cr has been spent, with the remaining INR 20-30 Cr expected to be incurred by March 2026 via internal accruals.

Credit Rating & Borrowing

Not disclosed in available documents; however, the company maintains a conservative leverage position with a Net Debt to Equity ratio of 0.1x and net debt of INR 73 Cr as of September 30, 2025.

⚙️ Operational Drivers

Raw Materials

Mineral-based chemistries and vitamins (specific minerals like calcium are implied by the excipient portfolio). Raw materials consumed accounted for INR 164.8 Cr in FY25, representing approximately 32.8% of total revenue.

Import Sources

Not explicitly disclosed, though the company operates globally and manages international supply chains to service 100 countries.

Capacity Expansion

Current manufacturing capacity is 72,246 MT across 4 facilities. A Greenfield expansion in Dahej will add 51,200 MT, bringing total capacity to 123,446 MT. Additionally, a battery material facility with 25,000 MT capacity is targeted for early 2027.

Raw Material Costs

Cost of materials consumed was INR 103.3 Cr in H1 FY26, up 54% from INR 67.1 Cr in H1 FY25, primarily due to the NSS acquisition and business mix changes.

Manufacturing Efficiency

Overall capacity utilization is approximately 50%. The Pharma, Food, and Nutrition vertical operates at ~65% utilization, nearing its optimum level of 70%, which triggered the current Greenfield expansion.

Logistics & Distribution

Other expenses (including distribution and global sales team costs) rose to INR 58.7 Cr in H1 FY26 from INR 52.2 Cr in H1 FY25, representing 20.4% of H1 revenue.

📈 Strategic Growth

Expected Growth Rate

26%

Growth Strategy

Growth will be driven by the integration of the NSS acquisition (Ireland), which provides immediate access to the infant nutrition market, and the expansion into battery materials with a 25,000 MT facility. The company is also shifting to a direct sales model in the US and Europe to capture 15-20% additional margin previously held by distributors.

Products & Services

Mineral-based pharmaceutical excipients, specialty ingredients for infant and clinical nutrition, and advanced materials for batteries.

Brand Portfolio

Sudeep Pharma, Nutrition Supplies and Services (NSS).

New Products/Services

Entry into the high-growth battery material segment with a dedicated facility in Dahej, Gujarat, expected to contribute to revenue by FY27.

Market Expansion

Expansion into Europe via the 85% stake acquisition of NSS in May 2025 and strengthening presence in Latin America with localized stocking.

Market Share & Ranking

Sudeep is the only Indian company approved to supply the three largest global infant nutrition companies, a process that typically takes 5-7 years.

Strategic Alliances

Acquired 85% stake in Nutrition Supplies and Services (NSS), Ireland, to bypass the 4-5 year regulatory approval timeline for infant nutrition.

🌍 External Factors

Industry Trends

The industry is seeing a 'China Plus One' shift; Sudeep is positioning itself as one of the first scalable suppliers of specialty ingredients outside of China.

Competitive Landscape

Limited competition in India and China for its specific technology-led functional ingredients due to high regulatory and customer approval hurdles.

Competitive Moat

High barriers to entry due to a 5-7 year customer approval cycle in infant nutrition and complex regulatory requirements. Sudeep's status as the only Indian supplier to the top 3 global infant nutrition firms provides a durable competitive advantage.

Macro Economic Sensitivity

Sensitive to global economic growth and interest rates, as 61% of revenue is international.

Consumer Behavior

Increased demand for clinical and infant nutrition is driving the focus on the Specialty Ingredients vertical.

Geopolitical Risks

Exposure to international trade regulations and potential tariff impacts, particularly in the U.S. market.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to stringent product-specific regulatory approvals in the US and Europe; the company currently holds 10 such approvals.

Taxation Policy Impact

Effective tax rate was approximately 24.2% in FY25 (INR 44.2 Cr tax on INR 182.8 Cr PBT).

⚠️ Risk Analysis

Key Uncertainties

Integration risks associated with the NSS acquisition and the successful commercialization of the new battery materials segment by 2027.

Geographic Concentration Risk

61% of revenue is derived from international markets, with the U.S. being the largest single market, creating high sensitivity to U.S. trade policies.